Terrance P. Coyne Insider Trading Activity
Terrance P. Coyne has been net-selling over the last 12 months with 0 purchases and 32 sales across 1 company.
RPRX is the most-traded position with 32 trades. The largest single transaction was a sale of RPRX for $4.7M on Feb 3, 2026.
Performance Scorecard
Forward stock performance after each transaction by Terrance P. Coyne. Buy returns measure price movement after open-market purchases; sell-avoided measures the loss avoided after open-market sales. Success rate counts trades where the insider's direction was right.
| PERIOD | AVG BUY RETURN | AVG SELL AVOIDED | SUCCESS RATE | TRADES |
|---|---|---|---|---|
| 30 days | — | -5.3% | 13% | 32 |
| 90 days | — | -19.3% | 0% | 30 |
| 120 days | — | -24.4% | 0% | 28 |
Performance based on stock price movement after each transaction date. Past results do not predict future returns. Not financial advice.
Price & Trades
Pro: Trade MarkersRPRX · Royalty Pharma plc
🔒 Subscribe to see trade entries
Pro members see exactly when Terrance P. Coyne bought and sold RPRX.
Upgrade to ProRecent Trades
| DATE | TICKER | TYPE | SHARES | PRICE | VALUE | Δ OWNED | ROLE | FILING |
|---|---|---|---|---|---|---|---|---|
Apr 28, 2026 | RPRX | Sell | 32,916 | $49.78 | $1.6M | −100.0% | CFO | |
Apr 28, 2026 | RPRX | Sell | 1,875 | $49.78 | $93K | −4.5% | CFO | |
Apr 1, 2026 | RPRX | Sell | 1,875 | $48.33 | $91K | −4.3% | CFO | |
Apr 1, 2026 | RPRX | Sell | 32,916 | $48.33 | $1.6M | −50.0% | CFO | |
Mar 23, 2026 | RPRX | Sell | 32,916 | $45.53 | $1.5M | −33.3% | CFO | |
Mar 23, 2026 | RPRX | Sell | 1,875 | $45.53 | $85K | −4.1% | CFO | |
Mar 2, 2026 | RPRX | Sell | 10,429 | $47.01 | $490K | −9.6% | CFO | |
Mar 2, 2026 | RPRX | Sell | 22,487 | $46.67 | $1.0M | −17.1% | CFO | |
Mar 2, 2026 | RPRX | Sell | 1,292 | $46.67 | $60K | −2.7% | CFO | |
Mar 2, 2026 | RPRX | Sell | 583 | $47.01 | $27K | −1.3% | CFO | |
Feb 23, 2026 | RPRX | Sell | 32,916 | $45.32 | $1.5M | −20.0% | CFO | |
Feb 23, 2026 | RPRX | Sell | 1,875 | $45.32 | $85K | −3.8% | CFO | |
Feb 4, 2026 | RPRX | Sell | 1,087 | $43.29 | $47K | −4.5% | CFO | |
Feb 4, 2026 | RPRX | Sell | 19,076 | $43.29 | $826K | −10.4% | CFO | |
Feb 3, 2026 | RPRX | Sell | 6,195 | $42.84 | $265K | −20.5% | CFO | |
Feb 3, 2026 | RPRX | Sell | 108,759 | $42.84 | $4.7M | −37.2% | CFO | |
Feb 2, 2026 | RPRX | Sell | 5,843 | $42.08 | $246K | −16.2% | CFO | |
Feb 2, 2026 | RPRX | Sell | 102,581 | $42.08 | $4.3M | −26.0% | CFO | |
Jan 20, 2026 Filed 3d late | RPRX | Sell | 65,832 | $39.35 | $2.6M | −14.3% | CFO | |
Jan 20, 2026 Filed 3d late | RPRX | Sell | 3,750 | $39.35 | $148K | −9.4% | CFO | |
Jan 2, 2026 | RPRX | Sell | 65,832 | $38.42 | $2.5M | −12.5% | CFO | |
Jan 2, 2026 | RPRX | Sell | 3,750 | $38.42 | $144K | −8.6% | CFO | |
Dec 15, 2025 | RPRX | Sell | 65,832 | $38.36 | $2.5M | −11.1% | CFO | |
Dec 15, 2025 | RPRX | Sell | 3,750 | $38.36 | $144K | −7.9% | CFO | |
Dec 1, 2025 | RPRX | Sell | 65,832 | $39.87 | $2.6M | −10.0% | CFO | |
Dec 1, 2025 | RPRX | Sell | 3,750 | $39.87 | $149K | −7.4% | CFO | |
Nov 24, 2025 | RPRX | Sell | 55,146 | $38.67 | $2.1M | −7.6% | CFO | |
Nov 24, 2025 | RPRX | Sell | 10,686 | $37.96 | $406K | −1.6% | CFO | |
Nov 24, 2025 | RPRX | Sell | 3,126 | $38.67 | $121K | −5.7% | CFO | |
Nov 24, 2025 | RPRX | Sell | 624 | $37.96 | $24K | −1.2% | CFO | |
Nov 17, 2025 | RPRX | Sell | 65,844 | $39.30 | $2.6M | −8.3% | CFO | |
Nov 17, 2025 | RPRX | Sell | 3,750 | $39.30 | $147K | −6.4% | CFO |
Top Companies Traded
| TICKER | COMPANY | TRADES | TOTAL VOLUME |
|---|---|---|---|
| RPRX | Royalty Pharma plc | 32 | $34.8M |
Other insiders at Royalty Pharma plc
2 other tracked filers at RPRX.